Ultragenyx Pharmaceutical (RARE)
(Delayed Data from NSDQ)
$28.71 USD
-0.77 (-2.61%)
Updated Sep 17, 2025 04:00 PM ET
After-Market: $28.72 +0.01 (0.03%) 7:34 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
RARE 28.71 -0.77(-2.61%)
Will RARE be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for RARE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RARE
IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome
RARE Reports Positive Long-Term Data From Metabolic Disorder Study
RARE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y
Ultragenyx (RARE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Earnings Preview: Verastem (VSTM) Q2 Earnings Expected to Decline
Other News for RARE
Pocket Pivot appears for RARE after 1.66% move
20 Day Moving Average Resistance appears for RARE after 4.32% move
Tracking Baker Brothers Portfolio - Q2 2025 Update
Is RARE ready to move lower? Fell Below 20 Day Moving Average shows up after dropping 2.95%
Non-ADX 1,2,3,4 Bullish appears for RARE after 0.19% move